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Abstract  
Aim: To determine factors, overall and by sex, associated with self-reported gastro-
oesophageal reflux disease (GORD) in chronic obstructive pulmonary disease (COPD) 
patients, and to evaluate relationships between GORD, its modification by acid suppression 
medications (Proton Pump Inhibitors[PPI]/histamine-2 receptor antagonists[H2RA]) and 
exacerbations of COPD and mortality. 
  
Methods: Logistic regression was used to determine factors associated with GORD; Cox 
proportional hazards models were used to calculate adjusted hazard ratios (HRs) and 95% 
confidence intervals (CIs) for GORD and risk of exacerbation and death. 
 
Results: Among 2,135 COPD patients from the ECLIPSE cohort, 547 patients self-reported 
GORD, with female preponderance; 237 were taking PPI/H2RA. Risk factors for GORD did 
not differ by sex. When compared to patients who did not report GORD or use of PPI/H2RA, 
patients with GORD and taking PPI/H2RA had a significantly increased risk of exacerbation 
(HR=1.58, 95%CI=1.35-1.86); risk was also increased for patients reporting GORD only or 
PPI/H2RA use only (HR=1.21 [1.04-1.40] and 1.33 [1.08-1.65], respectively). Similar 
findings were observed for risk of hospitalised exacerbation. GORD was not associated with 
mortality. 
 
Conclusion: GORD in COPD patients is highly prevalent, and risk factors did not differ by 
sex. Use of PPI/H2RA and self-reported GORD were associated with increased risk of 
moderate-to-severe and hospitalised exacerbations. 
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Abbreviations  
BODE  Body mass index, airflow Obstruction, Dyspnea and Exercise capacity; 
BMI  Body mass index 
CES-D  Center for Epidemiologic Studies of Depression Scale  
CI  Confidence interval 
COPD  Chronic obstructive pulmonary disease 
ECLIPSE Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints 
FACIT-F  Functional Assessment of Chronic Illness Therapy – Fatigue questionnaire 
FEV1  Forced Expiratory Volume  
FVC   Forced Vital Capacity 
GORD  Gastro-oesophageal reflux disease 
H2RA  Histamine-2 receptor antagonist  
HR  Hazard ratio 
mMRC  modified Medical Research Council  
NSAID  Non-steroidal anti-inflammatory drug 
OR  Odds ratio 
PPPY   Per person per year 
PPI   Proton pump inhibitor  
SD  Standard deviation 
SGRQ-C  St. George’s Respiratory Questionnaire for COPD patients 
Rx  Treatment 
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Introduction 
It is widely accepted that co-morbidities are common in, and contribute significantly to the 
morbidity and mortality associated with chronic obstructive pulmonary disease (COPD) [1]. 
A small but significant body of literature suggests that gastro-oesophageal reflux disease 
(GORD) is a common co-morbidity in COPD. Two studies with prospectively collected 
information suggest an association between GORD and exacerbations of COPD [2,3].  
Acid suppression medications are effective at reducing gastric acid production and a 
small randomized single-blind study suggested they may be effective in reducing 
exacerbations in COPD [4]; however, recent prospective studies do not support this finding 
[2,3].  
To further elucidate the relationship between GORD, acid suppression medications 
and exacerbations of COPD, we analysed data from the large well characterised longitudinal 
Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) 
cohort with the following aims: (1) to determine what factors are associated with the presence 
of GORD in COPD patients and whether these factors differ by sex, and (2) to evaluate the 
relationship between self-reported history of GORD, its modification by acid suppression 
medications and future exacerbations of COPD.   
 
 Methods 
Study design and patients 
Full details of the ECLIPSE study (SCO104960, NCT00292552) design and methods 
are described elsewhere [5]. In brief, clinically diagnosed COPD patients aged 40-75 years, 
with a smoking history ≥10 pack years, a post-bronchodilator Forced Expiratory Volume in 1 
second (FEV1) <80% of predicted value use, and a post-bronchodilator FEV1/Forced Vital 
Capacity (FVC) ratio <0.7 were recruited. Baseline measurements included lung function, 
anthropometric factors and others, and a blood sample was collected. Patients also completed 
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assessments of dyspnoea (modified Medical Research Council [mMRC] Dyspnoea scale), 
health status (St. George’s Respiratory Questionnaire for COPD patients [SGRQ-C]), fatigue 
(Functional Assessment of Chronic Illness Therapy – Fatigue questionnaire [FACIT-F]) and 
depression (Center for Epidemiologic Studies of Depression Scale [CES-D]). Self-reported 
information on respiratory symptoms, medication, smoking history, occupational exposure 
and co-morbidities were also collected at study entry. GORD was defined by questionnaire 
using the following question:  “Has a doctor ever told you that you had gastro-oesophageal 
reflux or heartburn?” Full lung function was measured on a smaller subset of 558 patients. 
After a baseline visit, patients were followed for a total of seven visits at three months, six 
months and every six months thereafter for three years.  
 ECLIPSE complies with the Declaration of Helsinki and Good Clinical Practice 
Guidelines, and has been approved by the ethics committees of the participating centres. All 
participants provided written informed consent. 
 
Study outcomes 
The COPD outcomes, moderate-severe exacerbations, hospitalised exacerbations, and death 
were reported during the three year follow-up.  
Exacerbations of COPD were determined by the patients’ primary clinicians or study 
personnel. Primary care clinicians were not given specific instructions on exacerbation 
diagnosis for the purposes of this study. Only exacerbations of COPD treated with antibiotics 
and/or systemic corticosteroids, or requiring hospitalisation were included in the analysis 
therefore fulfilling a health-care utilisation exacerbation definition of moderate or severe 
intensity.  The criteria for an exacerbation used during the study follow-up were identical to 
those used at study baseline when collecting data from patients on the number of 
exacerbations they had experienced in the previous year.  
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Exposure variables 
Self-reported history of a physician’s diagnosis of GORD (referred to hereafter as self-
reported GORD), treatment with acid suppression medications (proton pump inhibitor [PPI] 
and/or histamine-2 receptor antagonist [H2RA]) and self-reported GORD stratified by 
treatment with acid suppression therapy (PPI/H2RA) were used as primary exposure 
variables. Use of PPI and H2RA was defined as any use at the time of baseline visit.  
 
Statistical analysis 
All patients with at least 30 days of follow-up were included in the study. Only one patient 
withdrew from the study prior to 30 days follow-up. The individual’s patient time in study 
started with baseline visits and was censored at end of study (day 1,060), withdrawal, or 
death. 
Comparisons between descriptive summaries were examined using t-tests for means 
comparisons and chi-square tests for proportions. The incidence of exacerbations during the 
study period was summarised as a per-person-per-year rate with the differences between 
groups analysed using the nonparametric Kruskal-Wallis test. 
 
Factors associated with self-reported GORD  
Associations between GORD and possible explanatory factors were initially explored using 
univariable logistic regression calculating odds ratios (ORs) and 95% confidence intervals 
(CIs). Variables obtaining a p-value ≤0.2 were selected for inclusion in the manual stepwise 
model building process. For entry into and deletion from the final model, a p-value of 0.05 
was used. Age (per 10 year increase), sex (male, female), exacerbations in the 12 months prior 
to baseline (0-1, 2+), body mass index (BMI) (<18.5, 18.5-24.9, 25.0-29.9, ≥30.0 kg/m2), and 
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smoking status (past, current) were adjusted for in all multivariable models, where 
appropriate. Analyses were carried out for all patients combined, and by sex.   
The effect of plethysmography derived lung volumes, including markers of hyper-
inflation, and risk of GORD was examined in a subset of patients who completed this 
procedure (N=558) using univariable logistic regression analyses to estimate ORs and 95% 
CIs.  
Two sensitivity analyses were carried out: 1) GORD case definition of self-reported 
history of GORD and using PPI/H2RA at baseline, and 2) restricting the analyses to only 
those with complete data for the adjustment factors.  
 
GORD and time to first exacerbation and death 
We evaluated risk of moderate-to-severe exacerbations, exacerbations requiring hospital 
admission, and all-cause mortality, as separate primary end points, by presence of GORD and 
treatment with PPI/H2RA using Cox proportional hazards models calculating hazard ratios 
(HRs) and 95% CIs. The stratification term between GORD status and PPI/H2RA included 
four categories: 1) no GORD and no PPI/H2RA; 2) GORD and no PPI/H2RA; 3) no GORD 
and use of PPI/H2RA; and, 4) GORD and use of PPI/H2RA. No GORD and no PPI/H2RA 
use was used as the referent category. 
For all models, adjustments were made for age, sex, exacerbations in the 12 months 
prior to baseline, BMI, smoking status, FEV1 (per 100ml decrease), SGRQ total score (per 
increase of 4 points), and white-cell count (per increase of 1x10
3
/mm
3
); factors modelled 
previously [6]. A manual step-wise procedure for covariate selection was then followed using 
additionally all variables having an unconditional association with the outcome (p≤0.2).  
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Biomarker data were log10 transformed prior to all regression analyses where the 
normality assumption was not met. Variables with >10% missing data (fibrinogen and 
CCL18) were divided into quartiles, with an additional missing category included.  
Two sensitivity analyses were carried out: 1) including only patients who did not 
report an exacerbation in the 12 months prior to enrolment, and 2) restricting the analyses to 
only those with complete data for the adjustment factors. 
 
Results 
Characteristics of the patients 
A total of 2,135 COPD patients completed the question on history of GORD and were 
available for follow-up, of which 547 (26%) reported ever having been diagnosed with 
GORD. Amongst the patients who self-reported GORD, 237 (43%) were taking PPI/H2RA at 
baseline. There were an additional 127 patients who were taking PPI/H2RA but did not report 
a history of GORD. During the three year follow-up, 1,579 (74%) patients reported at least 
one exacerbation, of which, 668 (42%) required hospitalisation. A total of 201 (9%) patients 
died during follow-up. 
Baseline characteristics of the patients overall and by GORD status are reported in 
Table 1. As shown, patients with GORD were more likely to be female, have a higher BMI, 
less impaired lung function (measured by FEV1 percent predicted), but reported more 
symptoms and poorer health status and had higher levels of fibrinogen than patients without 
GORD. They were also more likely to have frequently exacerbated (=>2 events) in the 12 
months prior to the study baseline. Patients with GORD had a lower functional residual 
capacity (FRC) percent predicted and higher inspiratory capacity (IC) percent predicted 
(Supplementary Table 1). No other lung volume measures were associated with self-reported 
GORD.  
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Moderate-severe exacerbation rate during follow-up was 1.2 (SD: 1.42) events per patient per 
year, and was higher in patients who self-reported a physician’s diagnosis of GORD than 
those who did not (1.46 [SD: 1.52] versus 1.13 [SD: 1.37], respectively) (Table 1). 
Hospitalized exacerbation rate also differed by GORD status, but to a lesser extent (0.34 [SD: 
0.73] versus 0.27 [SD: 0.63], for history of GORD yes vs. no, respectively). 
 
Factors associated with self-reported GORD 
Factors unconditionally associated with GORD for all patients, and by sex are shown in 
Supplementary Table 2. In a multivariable model, self-reported history of GORD was 
significantly more likely to be reported by females (OR=1.80, 95% CI=1.41-2.29), older 
patients (OR=1.20, 95% CI=1.02-1.41 per 10 year increase),  overweight and obese (OR= 
1.40 [1.08-1.80], and 1.48 [1.11-1.98], respectively, for  25-29.9 and 30+ kg/m
2
, when 
compared to 18.5-24.9 kg/m
2
), in patients with less impaired lung function (OR=0.95, 95% 
CI=0.93-0.97), poorer health status (OR=1.06, 95% CI=1.04-1.09), history of chronic wheeze 
(OR=1.33, 95% CI=1.05-1.68) and history of asthma (OR=1.65, 95% CI=1.29-2.12), 
decreasing levels of neutrophils (OR=1.02, 95% CI=1.00-1.03), and increasing levels of IL6 
(OR=1.14, 95% CI=1.02-1.27) (Table 2). Although prevalence of GORD was significantly 
higher among females, the factors predicting GORD did not vary by sex. 
Sensitivity analyses restricting the analyses to only those with complete data for the 
adjustment factors did not materially change the results for the whole cohort, or by sex. When 
the definition of GORD was restricted to include only those who reported a history of GORD 
and were also using PPI/H2RA at baseline, the effect of most covariates was marginally 
strengthened, but the overall interpretation of the models did not change for the whole cohort 
(N=237 cases), or by sex.  
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GORD and exacerbations during follow-up 
Unadjusted analyses showed that for moderate-severe exacerbations, time to first exacerbation 
was shorter in patients with GORD compared to those without GORD (p<0.0001) (Figure 
1A). In addition, COPD patients taking PPI/H2RA also had a shorter time to first 
exacerbation independent of whether or not they reported GORD (p=0.007 and 0.002 with 
GORD and no GORD, respectively) (Figures 1B and 1C). Further, patients with a self-
reported history of GORD and also those treated with PPI/H2RA but no GORD had a shorter 
time to first hospitalised exacerbation (p=0.02 and 0.0003, respectively) (Figures 2A and 2C). 
Time to first hospitalised exacerbation did not differ by PPI/H2RA use in patients with a self-
reported history of GORD (Figure 2B).  
In a multivariable analysis, when compared to patients who did not report GORD or 
use of PPI/H2RA, the population with GORD and on medication had a significantly increased 
risk of exacerbation (HR=1.58 [95%CI=1.35-1.86]); the risk was also increased for patients 
who reported GORD only or the use of PPI/H2RA only (HR=1.21 [1.04-1.40] and 1.33 [1.08-
1.65], respectively) (Table 3). Similarly, self-reported history of GORD was significantly 
associated with hospitalised exacerbations (HR=1.28 [95%CI=1.02-1.60]), as was use of 
PPI/H2RA (HR=1.45, (1.07-1.97]); however, when self-reported GORD and medication were 
combined, although increased, the risk was not significant (HR=1.26 [0.97-1.63]) (Table 4). 
Self-reported history of GORD was not significantly associated with all-cause 
mortality (HR= 0.88 [95%CI=0.58-1.34], p=0.6), nor was the use of PPI/H2RA in GORD and 
non-GORD sufferers (HR = 1.36 [0.81-2.28], p=0.2; 0.87 [0.55-1.40], p=0.6, respectively). 
When restricting the analysis to patients who did not exacerbate in the 12 months prior 
to baseline, the effect of GORD and use of PPI/H2RA was similar to the final models for 
moderate-severe exacerbations and hospitalised exacerbations. The results did also not 
materially change when restricting to patients with complete data for the adjustment factors. 
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Discussion 
In this cohort of COPD patients, we found that self-report of GORD diagnosis or use 
of acid suppression medications (PPI and/or H2RA) at baseline were associated with a 20-
60% increased risk of moderate-severe exacerbations and hospitalised exacerbations during 
the three years of follow-up. In addition, the use of PPI/H2RA in the presence of GORD also 
significantly increased the risk of exacerbations, but not differently from the effect of the self-
reported history of GORD only or use of PPI/H2RA only. Self-reported history of GORD or 
use of PPI/H2RA was not associated with all-cause mortality.   
Self-reported GORD was highly prevalent among patients with COPD (26%), with 
significantly more women than men reporting a history of GORD (31% vs 23%, 
respectively). Although GORD was more common in women, no specific markers of such 
preponderance to GORD in females were identified.  
There is now information from multiple studies employing different designs to suggest 
the importance of GORD in COPD. Regular GORD symptoms were found to be as much as 
three times more prevalent in patients with COPD than the general population [7] and, 
smokers without COPD [8]. Despite the prominence of GORD in COPD, there is little known 
about the pathology of this comorbidity. Potential mechanisms include increased intra-
abdominal pressure (e.g with coughing), hyper-expansion displacing the diaphragm 
(discussed later), increased trans-diaphragmatic pressure secondary to airflow obstruction, 
altered autonomic tone of the lower oesophageal sphincter (either as part of COPD, or as a 
consequence of medication such as salbutamol) and use of gastro-irritant medication such as 
steroids [9]. The relationship between GORD and COPD is complex due to varying reflux 
presentation, which may be proximal or distal, acidic or not, and gaseous or liquid. Moreover, 
due to poor correlation between GORD symptoms, endoscopic findings and pH impedance 
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studies, there is paucity of standardised patient-reported questionnaires that can aid clinical 
diagnosis or be used in clinical studies. 
Similarly to findings reported from other studies, we found GORD to be more 
frequent in women than men [3,10,11]. In addition to these studies we explored in-depth, 
factors driving this differential reporting by sex but, despite having a comprehensive dataset, 
we did not detect any determinants of GORD that would differ by sex.  
It has been suggested that GORD may be more common in patients with hyper-
inflation, as a result of caudal displacement of the diaphragm [12]; however, we did not find 
associations between physiological indices of hyper-inflation such as residual volume and 
self-reported history of GORD.  
The increased risk of exacerbation in GORD sufferers has been reported in other 
studies [2,3,13-17]. Little is known about this association, but it is thought that the 
relationship may be reciprocal: exacerbations with cough and hyper-expansion may result in 
more reflux, and/or refluxate may result in exacerbation through aspiration and/or 
microaspiration, and/or vagally mediated reflex cough. This is important given the impact of 
exacerbations in COPD and the urgent need for novel interventions to reduce the frequency 
and severity of exacerbations.  
A hypothesis potentially explaining the risk of increased exacerbations in patients 
taking acid suppression medications would be that non-acidic reflux is more important in 
COPD, and that acid suppression medication use by reducing acid-associated symptoms may 
reduce patients’ presentation. Non-acidic reflux may consequently be more likely to result in 
aspiration as protective cough reflexes are not stimulated. The COPDGene study [3] also 
reported an association between GORD and frequent exacerbations with and without the use 
of PPI drugs. This is in contrast to findings from the Copenhagen City Heart Study where acid 
suppression medications were not associated with risk of exacerbation in those reporting 
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GORD [2]. Our study showed that the presence of GORD, either as a self-reported diagnosis 
or as use of PPI/H2RA, is associated with an increased risk of exacerbations. Newly, we 
showed that COPD patients were at an increased risk of both moderate-severe and 
hospitalised exacerbations even if they had no report of history of GORD but were using 
PPI/H2RA.  
As patients were not asked at recruitment about the reasons for medication 
prescription, it is unknown why some patients were taking PPI/H2RA in the apparent absence 
of GORD. It is possible that some patients may have been using PPI/H2RA for GORD 
without them recalling the GORD the diagnosis. It is also common practice in some countries 
to use PPI/H2RA in an attempt to reduce the gastro-irritant potential of steroid and non-
steroidal anti-inflammatory drugs (NSAIDs) that are relevant in a population with COPD. Of 
the 127 patients taking PPI/H2RA and not reporting history of GORD, 11 (18%) reported 
taking NSAIDs. 
To date there are no randomised double-blind controlled trials of interventions to 
reduce gastric acidity, or reflux in COPD designed to reduce exacerbations. In a 12-month, 
randomised, single-blind trial of lansoprazole in 100 patients, patients on active drug had a 
lower exacerbation frequency (0.34 versus 1.18 per year p<0.001) [4]. Interestingly, this study 
hypothesised on anti-inflammatory actions of the drug and patients with symptoms of GORD 
were excluded. Macrolide drugs reduce exacerbations in COPD [18] but the mechanism 
remains obscure: One potential mechanism is through an action on gastric motility as the 
drugs are motilin agonists. A lack of effectiveness of acid suppression therapy on reducing the 
exacerbation of COPD rate can be a result of several possibly co-occurring factors including 
the real lack of effect, multifactorial origins of exacerbations of COPD, and confounding by 
indication, whereby patients with more severe GORD are more frequently treated with acid 
suppression therapy. 
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The strengths of our study are the large and carefully characterised patient population 
and three years of follow-up information. The main limitation pertains to the GORD 
ascertainment and lack of measures specifically related to GORD. Similarly to COPDGene 
[3] we used a self-report of GORD diagnosis and the use of PPI/H2RA as markers of possible 
GORD. To date, only one study [17] has used a validated standardized questionnaire to 
determine history of GORD making comparisons of findings between studies difficult. The 
gold standards for the diagnosis of GORD are esophagogastroduodenoscopy and 24-hour 
esophageal pH impedance monitoring, both of which have not been measured in prospective 
COPD populations. The correlation between GORD symptoms, endoscopic findings, and 
gold-standard pH-impedance monitoring is known to be poor [9]. Larger studies are needed to 
clarify the significance of acid suppression medication use and COPD exacerbations in both 
the presence and absence of GORD. 
In summary, GORD in COPD is highly prevalent and more commonly reported by 
women. Use of PPI/H2RA and self-reported history of GORD were associated with an 
increased risk of moderate-to-severe exacerbation and hospitalised exacerbations.  
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Table 1: Baseline characteristics of the COPD patients and summary of exacerbation of 
COPD during follow-up, by gastro-oesophageal reflux disease (GORD) status* 
Baseline characteristic All patients 
(n=2,135) 
Mean (SD) 
GORD (Yes) 
(n=547)   
Mean (SD)  
GORD (No) 
(n=1558) 
Mean (SD) 
p-value 
Age (years) 63.4 (7.1) 63.5 (6.9) 63.4 (7.2) 0.9 
Female, n(%) 742 (34.8) 233 (42.6) 509 (32.1) <0.0001* 
GOLD Stage, n(%)     
  Stage 2 943 (44.2) 285 (52.1) 658 (41.4) <0.0001
*
 
  Stage 3 899 (42.1) 203 (37.1) 696 (43.8)  
  Stage 4 293 (13.7) 59 (10.8) 234 (14.7)  
Current smoker, n(%)  772 (36.2) 191 (34.9) 581 (36.6) 0.5 
  Pack-years   48.6 (27.1)   51.0 (28.1)   47.8 (26.7)   0.02 
Body mass index, kg/m
2
, n(%)     
  <18.5 108 (5.1) 17 (3.1) 91 (5.7) <0.0001
*
 
  18.5-24.9 783 (36.7) 169 (30.9) 614 (38.7)  
   25.0-29.9 760 (35.6) 211 (38.6) 549 (34.6)  
  ≥30 484 (22.7) 150 (27.4) 334 (21.0)  
FEV1 (l) 1.3 (0.5) 1.4 (0.5) 1.3 (0.5) 0.1 
FEV1 (% predicted) (n=2,131) 48.2 (15.7) 50.8 (15.6) 47.4 (15.7) <0.0001 
FEV1/FVC (%) (n=2,131) 44.7 (11.5) 46.0 (11.6) 44.3 (11.5) 0.004 
Emphysema (LAA%)  17.7 (12.3) 16.5 (11.1) 18.1 (12.6) 0.02 
mMRC Dyspnoea Score (2+), n(%)  1106 (53.2) 307 (57.4) 799 (51.8) 0.02 
Depression (CES-D score) 11.4 (9.3) 13.2 (9.5) 10.8 (9.1) <0.0001 
Fatigue (FACIT-F score) 35.1 (10.7) 32.8 (11.0) 35.9 (10.4) <0.0001 
SGRQ Total Score 48.1 (18.3) 51.6 (17.0) 46.9 (18.6) <0.0001 
BODE Index 3.2 (2.1) 3.0 (2.1) 3.2 (2.1) 0.05 
Chronic wheeze, n(%)  842 (39.4) 277 (50.6) 565 (35.6) <0.0001 
Chronic cough, n(%) 1051 (49.2) 281 (51.4) 770 (48.5) 0.2 
Chronic phlegm, n(%) 1088 (51.0) 296 (54.1) 792 (49.9) 0.09 
Asthma history, n(%) 489 (22.9) 182 (33.3) 307 (19.3) <0.0001 
Peptic ulcer, n(%) 218 (10.2) 114 (20.8) 104 (6.6) <0.0001 
Cardiovascular comorbidity, n(%) 713 (33.4) 186 (34.0) 527 (33.2) 0.7 
Diabetes Mellitus, n(%) 213 (10.0) 62 (11.3) 151 (9.5) 0.2 
Anxiety, n(%) 351 (16.4) 155 (28.3) 196 (12.3) <0.0001 
White blood cell count (109/l) 7.9 (2.3) 7.9 (2.2) 7.9 (2.3) 0.8 
Fibrinogen (mg/dl) 455.1 (103.9) 468.3 (107.2) 450.5 (102.4) 0.001 
hsCRP (mh/l) 6.8 (11.6) 7.0 (10.4) 6.7 (11.9) 0.5 
CC-16 (ng/ml) 5.6 (3.3) 5.6 (3.3) 5.6 (3.3) 0.9 
CCL-18 (ng/ml)  112.9 (43.3) 116.1 (42.8) 111.8 (43.4) 0.06 
SPD (ng/ml)  135.7 (76.6) 130.1 (73.2) 137.6 (77.7) 0.05 
H2RA, n(%) 65 (3.0) 43 (7.9) 22 (1.4) <0.0001 
PPI, n(%) 305 (14.3) 199 (36.4) 106 (6.7) <0.0001 
PPI and/or H2RA, n(%) 364 (17.0) 237 (43.3) 127 (8.0) <0.0001 
Any exacerbation in prior year, 
n(%) 1011 (47.4) 264 (48.3) 747 (47.0) 0.6 
≥2 exacerbations in prior year, 
n(%) 466 (21.8) 140 (25.6) 326 (20.5) 0.01 
     
Follow-up information     
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Baseline characteristic All patients 
(n=2,135) 
Mean (SD) 
GORD (Yes) 
(n=547)   
Mean (SD)  
GORD (No) 
(n=1558) 
Mean (SD) 
p-value 
Exacerbation rate (PPPY)     
  Moderate-to-severe exacerbations 1.22 (1.42) 1.46 (1.52) 1.13 (1.37) <0.0001 
    Requiring hospitalisation    0.28 (0.66)   0.34 (0.73)   0.27 (0.63)   0.02 
Died during follow-up (%) 202 (9.5) 46 (8.4) 156 (9.8) 0.3 
*
Global p-value 
For abbreviations, see list of abbreviations 
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Table 2: Factors associated with self-reported gastro-oesophageal reflux disease (GORD) in COPD patients, overall and by sex using a step-wise 
multivariable model 
  All patients (n=1,925)  Males (n=1,339)  Females (n=718) 
Baseline characteristic  OR (95% CI)  p-value  OR (95% CI)  p-value  OR (95% CI)  p-value 
Sex – female vs male  1.80 (1.41-2.29)  <0.0001         
Exacerbation during previous 
year – 2+ vs 0-1 
 
1.10 (0.85-1.43) 
 
0.5 
 
1.14 (0.82-1.59) 
  
0.4 
 
1.08 (0.74-1.59) 
 
0.7 
Age – per 10 year increase  1.20 (1.02-1.41)  0.03  1.25 (1.02-1.52)  0.03  1.28 (0.98-1.66)  0.07 
Smoking status – past vs 
current 
 
0.97 (0.77-1.23) 
 
0.8 
 
 0.85 (0.64-1.13) 
 
0.3 
 
1.14 (0.79-1.65) 
 
0.5 
Body mass index, kg/m
2
             
  <18.5  0.65 (0.36-1.16)  0.003*  1.24 (0.60-2.58)  0.02*  0.30 (0.12-0.74)     0.02* 
  18.5-24.9  1.00      1.00      1.00   
   25.0-29.9  1.40 (1.08-1.80)    1.53 (1.10-2.12)    1.17 (0.79-1.73)   
  ≥30  1.48 (1.11-1.98)    1.71 (1.20-2.44)     1.26 (0.81-1.96)   
FEV1 – per 100ml decrease  0.95 (0.93-0.97)  <0.0001  0.94 (0.91-0.97)  <0.0001  0.95 (0.90-1.00)  0.03 
SGRQ total score for COPD  
– per increase of 4 points 
 
1.06 (1.04-1.09) 
 
<0.0001 
 
1.06 (1.03-1.10) 
 
  <0.0001 
 
1.06 (1.02-1.10) 
 
0.007 
Neutrophils – per 1% 
decrease 
 
1.02 (1.00-1.03) 
 
0.02 
 -  -  -  - 
Il6 – per increase of 1SD on 
log scale 
 
1.14 (1.02-1.27) 
 
0.02 
 -  -  -  - 
Chronic wheeze – ever vs 
never 
 
1.33 (1.05-1.68) 
 
0.02 
 
1.34 (1.00-1.79) 
 
0.05 
 
1.48 (1.02-2.14) 
 
0.04 
Asthma – ever vs never  1.65 (1.29-2.12)  <0.0001  1.57 (1.14-2.18)  0.006  1.89 (1.32-2.72)  0.0005 
*Global p-value 
For abbreviations, see list of abbreviations 
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Table 3: The effect of gastro-oesophageal reflux disease (GORD) stratified by the use of acid 
suppression medications on time to first moderate-severe exacerbation in COPD patients, 
adjusting for other factors. N=1,991. 
 
Baseline characteristic  HR (95% CI)  p-value 
No GORD, no acid suppression 
Rx 
 
1.00 
 
 
Yes GORD, no acid suppression 
Rx 
 
1.21 (1.04-1.40) 
 
0.01 
No GORD, yes acid suppression 
Rx 
 
1.33 (1.08-1.65) 
 
0.008 
Yes GORD, yes acid 
suppression Rx 
 
1.58 (1.35-1.86) 
 
<0.0001 
Sex – female vs male  1.08 (0.96-1.21)  0.2 
Age – per 10 year increase  1.04 (0.96-1.13)  0.3 
Smoking status – past vs current 
 1.08 (0.96-1.21) 
 
 0.2 
 
Body mass index, kg/m
2
     
  <18.5  0.89 (0.70-1.13)  0.006 
  18.5-24.9  1.00   
   25.0-29.9  0.88 (0.78-0.99)   
  ≥30  0.78 (0.68-0.90)   
FEV1 – per 100ml decrease  1.06 (1.05-1.07)  <0.0001 
SGRQ Total Score for COPD  – 
per increase of 4 points 
 1.02 (1.01-1.03) 
 
 0.001 
 
Exacerbation during previous 
year – 2+ vs 0-1 
 
2.04 (1.80-2.30) 
 
<0.0001 
White-cell count – per increase 
of 1x10
3
/mm
3
 
 1.04 (1.01-1.06) 
 
 0.002 
 
Asthma – ever vs never  1.12 (0.98-1.26)  0.09 
Chronic wheeze – ever vs never  1.15 (1.02-1.29)  0.02 
*
Global p-value 
For abbreviations, see list of abbreviations 
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Table 4: The effect of gastro-oesophageal reflux disease (GORD) and the use of acid 
suppression medications on the time to first hospitalised exacerbation, adjusting for other 
factors. N=1,903 
 
Baseline characteristic  HR (95% CI)  p-value 
No GORD, no acid suppression 
Rx 
 
1.00 
 
 
Yes GORD, no acid suppression 
Rx 
 
1.28 (1.02-1.60) 
 
0.03 
No GORD, yes acid suppression 
Rx 
 
1.45 (1.07-1.97) 
 
0.02 
Yes GORD, yes acid 
suppression tx 
 
1.26 (0.97-1.63) 
 
0.08 
Sex – female vs male  0.72 (0.60-0.86)  0.0004 
Age – per 10 year increase  1.17 (1.03-1.33)  0.02 
Smoking status – past vs current  1.01 (0.84-1.21)  0.9 
Body mass index, kg/m
2
     
  <18.5  1.17 (0.82-1.66)  0.01* 
  18.5-24.9  1.00   
   25.0-29.9  0.81 (0.67-0.99)   
  ≥30  0.74 (0.59-0.92)   
FEV1 – per 100ml decrease  1.10 (1.08-1.13)  <0.0001 
SGRQ Total Score– per 
increase of 4 points 
 1.06 (1.04-1.08) 
 
 <0.0001 
 
Exacerbation during previous 
year – 2+ vs 0-1 
 1.24 (1.13-1.35) 
 
 <0.0001 
 
mMRC Score 2+ vs 0-1 
 
1.27 (1.04-1.55) 
 0.02 
 
CCL18 (quartiles)     
Q1  1.00  0.02* 
Q2  1.02 (0.79-1.32)   
Q3  0.88 (0.68-1.15)   
Q4  1.27 (0.99-1.63)   
White-cell count – per increase 
of 1x10
3
/mm
3
 
 1.06 (1.03-1.10) 
 
 0.0004 
 
Post-high school education  0.84 (0.70-1.00)  0.05 
Asthma – ever vs never  1.22 (1.01-1.47)  0.04 
*Global p-value 
For abbreviations, see list of abbreviations 
 
 
 
  
   
20 
 
Figure 1: Kaplan-Meier Plots for time to first moderate-to-severe exacerbation in COPD, by 
gastro-oesophageal reflux disease (GORD) status and use of PPI and/or H2RA medications 
 
Footnote: A) Kaplan-Meier plot for moderate-severe exacerbations, by GORD status; B) Kaplan-
Meier plot for moderate-severe exacerbations in patients with GORD, by those taking PPI and/or 
H2RA; C) Kaplan-Meier plot for moderate-severe exacerbations in patients WITHOUT GORD, by 
those taking PPI and/or H2RA 
 
For abbreviations, see list of abbreviations 
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Figure 2: Kaplan-Meier Plots for time to first hospitalised exacerbation in COPD, by gastro-
oesophageal reflux disease (GORD) status and use of PPI and/or H2RA medications 
 
A) Kaplan-Meier plot for hospitalised exacerbations, by GORD status; B) Kaplan-Meier plot for 
hospitalised exacerbations in patients with GORD, by those taking PPI and/or H2RA; C) Kaplan-
Meier plot for hospitalised exacerbations in patients WITHOUT GORD, by those taking PPI and/or 
H2RA.  
 
For abbreviations, see list of abbreviations 
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Supplementary Table 1: Lung volume measures and the risk of self-reported gastro-
oesophageal reflux disease in a COPD patient population (N=558): univariable analyses 
 
Baseline lung volume measures OR (95% CI) p-value 
Percent predicted normal residual volume 1.00 (0.99-1.00) 0.2 
Percent predicted normal total lung capacity 1.00 (0.99-1.01) 0.6 
Percent predicted normal functional residual 
capacity 
0.99 (0.99-1.00) 0.03 
Slow vital capacity (L) 0.90 (0.75-1.07) 0.2 
Inspiratory capacity (L) 1.09 (0.84-1.39) 0.5 
Percent predicted inspiratory capacity 1.02 (1.01-1.03) 0.001 
For abbreviations, see list of abbreviations 
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Supplementary Table 2: Odds ratios and 95% confidence intervals for factors associated 
with self-reported gastro-oesophageal reflux disease in a COPD patient population: 
univariable analyses 
 
Baseline characteristic All patients (n=2135) Males (n=1,393)  Females (n=742)  
 OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
Exacerbation in last 12 months (0-1, 2+) 1.33 (1.06-1.67) 0.01 1.25 (0.92-1.69) 
 
0.2 1.33 (0.94-1.88) 
 
0.1 
mMRC Dyspnea Score (0-1, 2+) 1.26 (1.03-1.53) 0.02 1.17 (0.91-1.51) 0.2 1.41 (1.02-1.94) 0.04 
Sex, female 1.57 (1.29-1.92) <0.0001 -  -  
Body mass index, kg/m
2
       
  <18.5 0.68 (0.39-1.17)  1.32 (0.65-2.68)  0.29 (0.12-0.69)  
  18.5-24.9 1.00 0.0001* 1.00 0.002* 1.00 0.003* 
   25.0-29.9 1.40 (1.11-1.76)  1.64 (1.21-2.24)  1.21 (0.84-1.75)  
  ≥30 1.63 (1.26-2.11)  1.86 (1.32-2.60)  1.51 (1.00-2.27)  
Age (per 10 yr increment) 1.01 (0.88-1.16) 0.9 1.02 (0.86-1.22) 0.8 1.07 (0.86-1.34) 0.5 
Smoker (past vs current) 1.08 (0.88-1.32) 0.5 0.96 (0.74-1.25) 0.8 1.30 (0.94-1.80) 0.1 
FEV1, per 100ml decrease 0.99 (0.97-1.00) 0.1 0.96 (0.94-0.99) 0.002 0.98 (0.94-1.02) 0.3 
FEV1 percent predicted, per 5% predicted 
increment 
1.07 (1.04-1.11) 
 
<0.0001 1.07 (1.03-1.12) 
 
0.0004 1.05 (1.00-1.10) 
 
0.07 
FEV1/FVC (%) 1.01 (1.00-1.02) 0.004 1.01 (1.00-1.02) 0.02 1.01 (0.99-1.02) 0.4 
GOLD grades        
    Stage 2 1.00  1.00  1.00  
    Stage 3 0.67 (0.55-0.83) <0.0001* 0.65 (0.50-0.86) 0.002* 0.76 (0.54-1.06) 0.1* 
    Stage 4 0.58 (0.42-0.80)  0.60 (0.41-0.89)  0.63 (0.36-1.10)  
FVC (l) 0.98 (0.88-1.09) 0.7 1.16 (1.01-1.34) 0.04 1.08 (0.84-1.38) 0.5 
SQRG Total Score  per 4 unit increment 1.05 (1.03-1.07) <0.0001 1.05 (1.02-1.07) 0.0006 1.06 (1.03-1.10) 0.0003 
Fatigue (FACIT-F score) 0.98 (0.97-0.98) <0.0001 0.98 (0.97-0.99) 0.003 0.97 (0.95-0.98) <0.0001 
Depression (CES-D score) 1.03 (1.02-1.04) <0.0001 1.03 (1.01-1.04) 0.0004 1.02 (1.01-1.04) 0.005 
Platelet count: 10 x 10^9/L increase 1.01 (1.00-1.03) 0.1 1.01 (0.99-1.02) 0.6 1.01 (0.98-1.03) 0.6 
Haemoglobin per 10g/L increment 0.88 (0.82-0.95) 0.001 0.93 (0.85-1.03) 0.2 0.90 (0.78-1.03) 0.1 
Neutrophils (per 1% decrease) 1.01 (1.00-1.02) 0.1 1.01 (0.99-1.02) 0.5 1.01 (0.99-1.03) 0.3 
Fibrinogen (mg/dL) (quartiles)       
Q1 1.00 0.008* 1.00 0.1* 1.00 0.08* 
Q2 1.11 (0.82-1.51)  1.18 (0.80-1.73)  0.97 (0.59-1.60)  
Q3 1.35 (1.00-1.82)  1.45 (1.00-2.12)  1.16 (0.70-1.90)  
Q4 1.60 (1.19-2.15)  1.49 (1.02-2.18)  1.66 (1.03-2.67)  
hsCRP (mg/L)  (per 1SD increment on log 
scale) 
1.14 (1.04-1.26) 
 
0.007 1.10 (0.97-1.25) 
 
0.2 1.25 (1.07-1.46) 
 
0.006 
SP-D (ng/ml)  (per 1SD increment on log scale) 0.90 (0.81-0.99) 0.03 0.99 (0.87-1.13) 0.9 0.80 (0.69-0.93) 0.005 
IL-6 (pg/ml)  (per 1SD increment on log scale) 1.12 (1.02-1.24) 0.02 1.11 (0.98-1.26) 0.1 1.17 (0.99-1.38) 0.07 
CC-18 (ng/ml)  (quartiles)       
Q1 1.00 0.2* 1.00 0.8* 1.00 0.01 * 
Q2 1.23 (0.91-1.67)  1.20 (0.81-1.80)  1.31 (0.81-2.11)  
Q3 1.32 (0.97-1.78)  1.05 (0.71-1.58)  1.99 (1.24-3.20)  
Q4 1.35 (1.00-1.83)  1.15 (0.77-1.70)  1.96 (1.21-3.19)  
Chronic wheeze (Y/N) 1.86 (1.53-2.26) <0.0001 1.73 (1.34-2.23) <0.0001 2.06 (1.50-2.83) <0.0001 
Asthma (Y/N) 2.08 (1.68-2.59) <0.0001 1.77 (1.32-2.38) 0.0002 2.27 (1.63-3.15) <0.0001 
Chronic cough (Y/N) 1.12 (0.92-1.36) 0.2 1.22 (0.95-1.57) 0.1 1.07 (0.79-1.46) 0.7 
Hypertension (Y/N) 1.22 (1.00-1.48) 0.05 1.21 (0.94-1.56) 0.1 1.22 (0.89-1.66) 0.2 
*Global p-value 
For abbreviations, see list of abbreviations 
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